Clinical trial
Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast…
NCT00129896 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00129896 |
|---|---|
| Title | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients |
| Official title | Open-label Phase I-II Clinical Trial to Evaluate Treatment With Myocet/Taxotere/Herceptin as Primary Chemotherapy Treatment for HER2neu Positive Breast Cancer Patients |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Cephalon Industry Sanofi Hoffmann-La Roche Amgen |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Myocet, Taxotere, Herceptin |
| Enrollment | 73 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | Feb 1, 2010 |
| First posted | Aug 12, 2005 |
| Last update posted | Mar 6, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: